BACKGROUND AND PURPOSE: Laparoendoscopic single-site surgery (LESS) is one of the most interesting surgical advances. We performed LESS adrenalectomy in three patients to assess feasibility, safety, and perioperative outcomes. PATIENTS AND METHODS: Three patients with nonfunctional adrenal masses underwent TriPort adrenalectomy. Demographics, perioperative, and pathological records were collected together with postoperative data. TriPort was used through a 3 cm subcostal incision with 10 mm 30 degrees optic and two 5 mm instruments. The specimens were extracted via a 10 mm bag instead of the optic. RESULTS: TriPort adrenalectomy was completed in all cases. The mean operative time was 200 minutes (mean blood loss, 40 mL). No perioperative complications were recorded. Pathology examination confirmed one adenoma, one lung cancer metastasis, and one myelolipoma.

BACKGROUND AND PURPOSE: Laparoendoscopic single-site surgery (LESS) is one of the most interesting surgical advances. We performed LESS adrenalectomy in three patients to assess feasibility, safety, and perioperative outcomes. PATIENTS AND METHODS: Three patients with nonfunctional adrenal masses underwent TriPort adrenalectomy. Demographics, perioperative, and pathological records were collected together with postoperative data. TriPort was used through a 3 cm subcostal incision with 10 mm 30 degrees optic and two 5 mm instruments. The specimens were extracted via a 10 mm bag instead of the optic. RESULTS: TriPort adrenalectomy was completed in all cases. The mean operative time was 200 minutes (mean blood loss, 40 mL). No perioperative complications were recorded. Pathology examination confirmed one adenoma, one lung cancer metastasis, and one myelolipoma. CONCLUSIONS: LESS adrenalectomy is feasible and safe, with favorable perioperative and short-term outcomes. It is technically more challenging than standard laparoscopy and requires advanced surgical skills. Prospective studies are needed for further conclusions

Assessing feasibility and safety of laparoendoscopic single-site surgery adrenalectomy: initial experience

Stefano Gidaro;Luigi Schips
2010-01-01

Abstract

BACKGROUND AND PURPOSE: Laparoendoscopic single-site surgery (LESS) is one of the most interesting surgical advances. We performed LESS adrenalectomy in three patients to assess feasibility, safety, and perioperative outcomes. PATIENTS AND METHODS: Three patients with nonfunctional adrenal masses underwent TriPort adrenalectomy. Demographics, perioperative, and pathological records were collected together with postoperative data. TriPort was used through a 3 cm subcostal incision with 10 mm 30 degrees optic and two 5 mm instruments. The specimens were extracted via a 10 mm bag instead of the optic. RESULTS: TriPort adrenalectomy was completed in all cases. The mean operative time was 200 minutes (mean blood loss, 40 mL). No perioperative complications were recorded. Pathology examination confirmed one adenoma, one lung cancer metastasis, and one myelolipoma. CONCLUSIONS: LESS adrenalectomy is feasible and safe, with favorable perioperative and short-term outcomes. It is technically more challenging than standard laparoscopy and requires advanced surgical skills. Prospective studies are needed for further conclusions
2010
BACKGROUND AND PURPOSE: Laparoendoscopic single-site surgery (LESS) is one of the most interesting surgical advances. We performed LESS adrenalectomy in three patients to assess feasibility, safety, and perioperative outcomes. PATIENTS AND METHODS: Three patients with nonfunctional adrenal masses underwent TriPort adrenalectomy. Demographics, perioperative, and pathological records were collected together with postoperative data. TriPort was used through a 3 cm subcostal incision with 10 mm 30 degrees optic and two 5 mm instruments. The specimens were extracted via a 10 mm bag instead of the optic. RESULTS: TriPort adrenalectomy was completed in all cases. The mean operative time was 200 minutes (mean blood loss, 40 mL). No perioperative complications were recorded. Pathology examination confirmed one adenoma, one lung cancer metastasis, and one myelolipoma.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11564/682771
Citazioni
  • ???jsp.display-item.citation.pmc??? 7
  • Scopus 20
  • ???jsp.display-item.citation.isi??? 23
social impact